Peng Lei, Du Chunxiao, Meng Chunyang, Li Jinze, You Chengyu, Li Xianhui, Zhao Pan, Cao Dehong, Li Yunxiang
Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, China.
Department of Clinical Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Front Oncol. 2021 Oct 13;11:702908. doi: 10.3389/fonc.2021.702908. eCollection 2021.
This meta-analysis aims to assess whether the Controlling nutritional status (CONUT) score before treatment can be an independent predictor of the prognosis of patients with urothelial cancer (UC).
The system searches Web of Science, PubMed, MEDLINE, China National Knowledge Infrastructure (CNKI), and Cochrane Library, and the search time is up to April 2021. Use STATA 16.0 and Engauge Digitizer 4.1 software for data processing and statistical analysis.
A total of 8 studies were included in this meta-analysis. The meta-analysis results show that compared with the low CONUT group, the high CONUT group has worse over survival (OS) [HR=1.58, 95%CI (1.34, 1.86), P=0.001], cancer-specific survival (CSS) [HR=2.03, 95%CI (1.25-3.29), P=0.04] and recurrence-free survival (RFS) [HR=1.97, 95%CI (1.15, 3.40), P=0.014]; for progression-free survival (PFS), or disease-free survival (DFS), the difference between the two groups was not statistically significant [HR=2.30, 95%CI (0.72, 7.32), P=0.158]. According to different carcinoma types, cut-off value, and region, subgroup analysis of OS was performed, and similar results were obtained.
Based on current evidence, this meta-analysis proves that the CONUT score of UC patients before treatment is an independent prognostic predictor. It performs well on OS, CSS, and RFS, but the conclusions on DFS/PFS need to be treated with caution.
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021251890, identifier CRD42021251890.
本荟萃分析旨在评估治疗前的控制营养状况（CONUT）评分是否可作为尿路上皮癌（UC）患者预后的独立预测指标。
系统检索Web of Science、PubMed、MEDLINE、中国知网（CNKI）和Cochrane图书馆，检索时间截至2021年4月。使用STATA 16.0和Engauge Digitizer 4.1软件进行数据处理和统计分析。
本荟萃分析共纳入8项研究。荟萃分析结果显示，与低CONUT组相比，高CONUT组的总生存期（OS）更差[风险比（HR）=1.58，95%置信区间（CI）（1.34，1.86），P=0.001]、癌症特异性生存期（CSS）[HR=2.03，95%CI（1.25 - 3.29），P=0.04]和无复发生存期（RFS）[HR=1.97，95%CI（1.15，3.40），P=0.014]；对于无进展生存期（PFS）或无病生存期（DFS），两组之间的差异无统计学意义[HR=2.30，95%CI（0.72，7.32），P=0.158]。根据不同的癌型、截断值和地区，对OS进行亚组分析，得到了类似的结果。
基于目前的证据，本荟萃分析证明UC患者治疗前的CONUT评分是一个独立的预后预测指标。它在OS、CSS和RFS方面表现良好，但关于DFS/PFS的结论需谨慎对待。
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021251890，标识符CRD42021251890。
